Comparative Pharmacology
Head-to-head clinical analysis: PAREDRINE versus PAREMYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAREDRINE versus PAREMYD.
PAREDRINE vs PAREMYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paredrine (hydroxyamphetamine) is a sympathomimetic amine that acts as an indirect-acting adrenergic agonist, displacing norepinephrine from presynaptic nerve terminals and inhibiting its reuptake, leading to activation of alpha- and beta-adrenergic receptors.
PAREMYD is a direct-acting vasodilator; its active metabolite, hydralazine, relaxes arteriolar smooth muscle by increasing cyclic guanosine monophosphate (cGMP) levels via inhibition of inositol trisphosphate (IP3) production, leading to reduced intracellular calcium and vasodilation.
5-10 mg intramuscularly (IM) or subcutaneously (SC) every 30-60 minutes as needed; intravenous (IV) dose: 2-5 mg every 5-10 minutes, not to exceed 50 mg total.
10 mg orally twice daily; maximum daily dose: 20 mg.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; may be prolonged in renal impairment.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 40 hours) necessitating dose adjustment.
Renal (approximately 80% as unchanged drug and metabolites); biliary/fecal (minor, <10%).
Primarily renal excretion of unchanged drug (60-80%) and hepatic metabolism (20-40%) with biliary-fecal elimination of metabolites.
Category C
Category C
Mydriatic
Mydriatic